Assenagon Asset Management S.A. Sells 3,280 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)

Assenagon Asset Management S.A. decreased its holdings in Blueprint Medicines Co. (NASDAQ:BPMC) by 3.3% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 97,353 shares of the biotechnology company’s stock after selling 3,280 shares during the quarter. Assenagon Asset Management S.A. owned approximately 0.15% of Blueprint Medicines worth $8,491,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Quarry LP acquired a new position in shares of Blueprint Medicines during the third quarter valued at $32,000. Covestor Ltd lifted its position in Blueprint Medicines by 206.7% during the 3rd quarter. Covestor Ltd now owns 598 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 403 shares during the period. Quantbot Technologies LP bought a new position in shares of Blueprint Medicines in the 3rd quarter valued at about $108,000. Values First Advisors Inc. acquired a new stake in Blueprint Medicines during the 3rd quarter worth $122,000. Finally, CWM LLC increased its holdings in Blueprint Medicines by 69.2% in the third quarter. CWM LLC now owns 1,870 shares of the biotechnology company’s stock valued at $173,000 after purchasing an additional 765 shares during the last quarter.

Wall Street Analyst Weigh In

BPMC has been the topic of several analyst reports. JPMorgan Chase & Co. started coverage on shares of Blueprint Medicines in a report on Thursday, November 14th. They issued an “overweight” rating and a $126.00 target price on the stock. Guggenheim restated a “buy” rating on shares of Blueprint Medicines in a report on Wednesday, December 11th. HC Wainwright reiterated a “buy” rating and set a $135.00 price objective on shares of Blueprint Medicines in a report on Friday, November 15th. Stephens reissued an “overweight” rating and issued a $140.00 price objective on shares of Blueprint Medicines in a research report on Thursday, January 2nd. Finally, Wells Fargo & Company decreased their target price on shares of Blueprint Medicines from $153.00 to $151.00 and set an “overweight” rating for the company in a research report on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Blueprint Medicines presently has an average rating of “Moderate Buy” and an average price target of $122.72.

Blueprint Medicines Trading Up 5.9 %

BPMC stock opened at $110.05 on Monday. Blueprint Medicines Co. has a 52 week low of $72.24 and a 52 week high of $121.90. The company has a debt-to-equity ratio of 1.09, a quick ratio of 3.27 and a current ratio of 3.32. The company’s 50-day simple moving average is $94.09 and its 200 day simple moving average is $95.22. The company has a market capitalization of $6.99 billion, a PE ratio of -52.16 and a beta of 0.61.

Blueprint Medicines (NASDAQ:BPMC) last announced its earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) EPS for the quarter, topping the consensus estimate of ($0.97) by $0.08. The company had revenue of $128.20 million for the quarter, compared to analysts’ expectations of $127.56 million. Blueprint Medicines had a negative net margin of 29.48% and a negative return on equity of 112.30%. The business’s revenue for the quarter was up 126.5% on a year-over-year basis. During the same period last year, the firm earned ($2.20) earnings per share. As a group, sell-side analysts anticipate that Blueprint Medicines Co. will post -3.68 earnings per share for the current year.

Insider Activity

In other Blueprint Medicines news, Director Jeffrey W. Albers sold 15,000 shares of the business’s stock in a transaction that occurred on Thursday, December 19th. The shares were sold at an average price of $89.77, for a total transaction of $1,346,550.00. Following the completion of the transaction, the director now directly owns 157,557 shares in the company, valued at $14,143,891.89. The trade was a 8.69 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Ariel Hurley sold 2,250 shares of the firm’s stock in a transaction on Monday, January 13th. The shares were sold at an average price of $100.00, for a total value of $225,000.00. Following the completion of the sale, the insider now directly owns 14,967 shares in the company, valued at approximately $1,496,700. This represents a 13.07 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 30,970 shares of company stock worth $2,914,246. 4.21% of the stock is currently owned by company insiders.

Blueprint Medicines Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.